RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer

R. Kang, W. Hou, Q. Zhang, R. Chen, Y. J. Lee, D. L. Bartlett, M. T. Lotze, D. Tang, H. J. Zeh

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

A hypoxic tumor microenvironment is characteristic of many cancer types, including one of the most lethal, pancreatic cancer. We recently demonstrated that the receptor for advanced glycation end products (RAGE) has an important role in promoting the development of pancreatic cancer and attenuating the response to chemotherapy. We now demonstrate that binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)α activation and promotes pancreatic tumor growth under hypoxic conditions. Hypoxia induces NF-?B-dependent and HIF1α-independent RAGE expression in pancreatic tumor cells. Moreover, the interaction between RAGE and mutant KRAS increases under hypoxia, which in turn sustains KRAS signaling pathways (RAF-MEK-ERK and PI3K-AKT), facilitating stabilization and transcriptional activity of HIF1α. Knock down of RAGE in vitro inhibits KRAS signaling, promotes HIF1α degradation, and increases hypoxia-induced pancreatic tumor cell death. RAGE-deficient mice have impaired oncogenic KRAS-driven pancreatic tumor growth with significant downregulation of the HIF1α signaling pathway. Our results provide a novel mechanistic link between NF-?B, KRAS, and HIF1α, three potent molecular pathways in the cellular response to hypoxia during pancreatic tumor development and suggest alternatives for preventive and therapeutic strategies.

Original languageEnglish (US)
Article numbere1480
JournalCell Death and Disease
Volume5
Issue number10
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hypoxia-Inducible Factor 1
Pancreatic Neoplasms
Neoplasms
Tumor Microenvironment
MAP Kinase Signaling System
Growth
Phosphatidylinositol 3-Kinases
Advanced Glycosylation End Product-Specific Receptor
Cell Death
Down-Regulation
Drug Therapy
Hypoxia

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. / Kang, R.; Hou, W.; Zhang, Q.; Chen, R.; Lee, Y. J.; Bartlett, D. L.; Lotze, M. T.; Tang, D.; Zeh, H. J.

In: Cell Death and Disease, Vol. 5, No. 10, e1480, 01.01.2014.

Research output: Contribution to journalArticle

Kang, R. ; Hou, W. ; Zhang, Q. ; Chen, R. ; Lee, Y. J. ; Bartlett, D. L. ; Lotze, M. T. ; Tang, D. ; Zeh, H. J. / RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. In: Cell Death and Disease. 2014 ; Vol. 5, No. 10.
@article{0d0d7c6066764da2933f9abb5b9bcb4d,
title = "RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer",
abstract = "A hypoxic tumor microenvironment is characteristic of many cancer types, including one of the most lethal, pancreatic cancer. We recently demonstrated that the receptor for advanced glycation end products (RAGE) has an important role in promoting the development of pancreatic cancer and attenuating the response to chemotherapy. We now demonstrate that binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)α activation and promotes pancreatic tumor growth under hypoxic conditions. Hypoxia induces NF-?B-dependent and HIF1α-independent RAGE expression in pancreatic tumor cells. Moreover, the interaction between RAGE and mutant KRAS increases under hypoxia, which in turn sustains KRAS signaling pathways (RAF-MEK-ERK and PI3K-AKT), facilitating stabilization and transcriptional activity of HIF1α. Knock down of RAGE in vitro inhibits KRAS signaling, promotes HIF1α degradation, and increases hypoxia-induced pancreatic tumor cell death. RAGE-deficient mice have impaired oncogenic KRAS-driven pancreatic tumor growth with significant downregulation of the HIF1α signaling pathway. Our results provide a novel mechanistic link between NF-?B, KRAS, and HIF1α, three potent molecular pathways in the cellular response to hypoxia during pancreatic tumor development and suggest alternatives for preventive and therapeutic strategies.",
author = "R. Kang and W. Hou and Q. Zhang and R. Chen and Lee, {Y. J.} and Bartlett, {D. L.} and Lotze, {M. T.} and D. Tang and Zeh, {H. J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/cddis.2014.445",
language = "English (US)",
volume = "5",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer

AU - Kang, R.

AU - Hou, W.

AU - Zhang, Q.

AU - Chen, R.

AU - Lee, Y. J.

AU - Bartlett, D. L.

AU - Lotze, M. T.

AU - Tang, D.

AU - Zeh, H. J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A hypoxic tumor microenvironment is characteristic of many cancer types, including one of the most lethal, pancreatic cancer. We recently demonstrated that the receptor for advanced glycation end products (RAGE) has an important role in promoting the development of pancreatic cancer and attenuating the response to chemotherapy. We now demonstrate that binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)α activation and promotes pancreatic tumor growth under hypoxic conditions. Hypoxia induces NF-?B-dependent and HIF1α-independent RAGE expression in pancreatic tumor cells. Moreover, the interaction between RAGE and mutant KRAS increases under hypoxia, which in turn sustains KRAS signaling pathways (RAF-MEK-ERK and PI3K-AKT), facilitating stabilization and transcriptional activity of HIF1α. Knock down of RAGE in vitro inhibits KRAS signaling, promotes HIF1α degradation, and increases hypoxia-induced pancreatic tumor cell death. RAGE-deficient mice have impaired oncogenic KRAS-driven pancreatic tumor growth with significant downregulation of the HIF1α signaling pathway. Our results provide a novel mechanistic link between NF-?B, KRAS, and HIF1α, three potent molecular pathways in the cellular response to hypoxia during pancreatic tumor development and suggest alternatives for preventive and therapeutic strategies.

AB - A hypoxic tumor microenvironment is characteristic of many cancer types, including one of the most lethal, pancreatic cancer. We recently demonstrated that the receptor for advanced glycation end products (RAGE) has an important role in promoting the development of pancreatic cancer and attenuating the response to chemotherapy. We now demonstrate that binding of RAGE to oncogenic KRAS facilitates hypoxia-inducible factor 1 (HIF1)α activation and promotes pancreatic tumor growth under hypoxic conditions. Hypoxia induces NF-?B-dependent and HIF1α-independent RAGE expression in pancreatic tumor cells. Moreover, the interaction between RAGE and mutant KRAS increases under hypoxia, which in turn sustains KRAS signaling pathways (RAF-MEK-ERK and PI3K-AKT), facilitating stabilization and transcriptional activity of HIF1α. Knock down of RAGE in vitro inhibits KRAS signaling, promotes HIF1α degradation, and increases hypoxia-induced pancreatic tumor cell death. RAGE-deficient mice have impaired oncogenic KRAS-driven pancreatic tumor growth with significant downregulation of the HIF1α signaling pathway. Our results provide a novel mechanistic link between NF-?B, KRAS, and HIF1α, three potent molecular pathways in the cellular response to hypoxia during pancreatic tumor development and suggest alternatives for preventive and therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84923123479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923123479&partnerID=8YFLogxK

U2 - 10.1038/cddis.2014.445

DO - 10.1038/cddis.2014.445

M3 - Article

C2 - 25341034

AN - SCOPUS:84923123479

VL - 5

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 10

M1 - e1480

ER -